ReviewDrugs1996
Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease.
Review in Drugs, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 68 citations in OpenAlex.
- Preventive administration of verapamil attenuates dextran sulfate sodium-induced colitis in mice.Experimental and therapeutic medicine · 2026Article
- The Role of Mechanically-Activated Ion Channels Piezo1, Piezo2, and TRPV4 in Chondrocyte Mechanotransduction and Mechano-Therapeutics for Osteoarthritis.Frontiers in cell and developmental biology · 2022Review
- Verapamil inhibits efflux pumps inVirulence · 2021Article
- Preventive Effect of Canstatin against Ventricular Arrhythmia Induced by Ischemia/Reperfusion Injury: A Pilot Study.International journal of molecular sciences · 2021Article
- Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis.BMC cardiovascular disorders · 2018Review
- Antianginal medications and long-term outcomes after elective catheterization in patients with coronary artery disease.Clinical cardiology · 2016Article
- Verapamil decreases the glucose-lowering effect of metformin in healthy volunteers.British journal of clinical pharmacology · 2014Article
- Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- Deacylative allylation: allylic alkylation via retro-Claisen activation.Journal of the American Chemical Society · 2011Article
- In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.Antimicrobial agents and chemotherapy · 2009Article
- Treatment of refractory angina.Ochsner journal · 2009Article
- Ivabradine: the evidence of its therapeutic impact in angina.Core evidence · 2008Article
- Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension.Drugs · 2005Review
- Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension.Drugs · 2002Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Verapamil has well proven efficacy in the treatment of patients with hypertension, and early studies indicated its efficacy in the treatment of coronary artery disease. The efficacy of verapamil relative to placebo in patients with stable angina pectoris is confirmed, and the drug is at least as effective as nifedipine, propranolol or metoprolol and of similar efficacy to bepridil and nicardipine when administered as a conventional or sustained release formulation. Verapamil is the first calcium antagonist to be shown in a double-blind study to significantly reduce mortality and reinfarction rate after acute myocardial infarction in patients without heart failure. In these patients, the reduction in mortality achieved with verapamil was similar to that reported with beta-adrenoceptor antagonists, suggesting that verapamil may be a suitable alternative to beta-blockers as secondary prevention in patients intolerant of these drugs. Recurrence of stenosis in patients who successfully undergo percutaneous transluminal coronary angioplasty (PTCA) limits the usefulness of the procedure. Verapamil has recently been shown to significantly reduce the rate of restenosis in patients with stable angina at risk of recurrence, although these initial results require confirmation. Verapamil, therefore, is effective in the treatment of patients with stable angina pectoris, appears to be an alternative to beta-blockers in selected patients as late start secondary prevention after acute myocardial infarction and has a potential role in preventing recurrent stenosis after PTCA, if initial results are confirmed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.